AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
Shares of AZN stock popped Thursday after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene. The post AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs appeared first on Investor's Business Daily.#azn #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill
AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight-loss and diabetes drugs Ozempic and Wegovy. AstraZeneca said Thursday it had reached an exclusive license…#astrazeneca #ecc5004 #glp1 #pascalsoriot #ozempic #wegovyormounjaro #novonordisk #wegovyandozempic #novonordisks #fda (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news
How safe is AstraZeneca's Covid jab? What rare complications can it cause? Who is taking legal action against the pharma giant? All you need to know
As Brits take AstraZeneca to court over deaths and injuries linked to its Covid jab we answer all your questions about the vaccine, the risks, and who could end up paying for compensation. (Source: the Mail online | Health)
Source: the Mail online | Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill —As Weight Loss Drug Market Grows
The drug is similar to Ozempic, which is commonly used for diabetes and weight loss. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 9, 2023 Category: Pharmaceuticals Authors: Ty Roush, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
Is AstraZeneca's Covid jab 'defective'? How firm that supplied 50million doses to the UK could face £90million lawsuit over rare blood clot side effect
Two cases brought against the pharmaceutical giant in the High Court could open the floodgates to dozens more Brits seeking legal compensation for similar injuries. (Source: the Mail online | Health)
Source: the Mail online | Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca signs deal for oral obesity drug and lifts profit outlook
Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 9, 2023 Category: Pharmaceuticals Source Type: news
Father claims AstraZeneca's Covid vaccine is 'defective' as the drugs giant faces a landmark High Court battle over the accusations
Bringing the court action is IT engineer Jamie Scott, who suffered a brain haemorrhage the day after his first AstraZeneca jab, leaving him with permanent brain damage. (Source: the Mail online | Health)
Source: the Mail online | Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca Ups Core EPS Guidance Despite Profit Miss
AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower third-quarter profit that missed forecasts. The Anglo-Swedish pharmaceutical giant said Thursday that it expects core earnings per share to increase by a low…#astrazeneca #anglo #swedish (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca Raises Profit Outlook on Demand for Cancer Drugs
(Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca ups annual outlook on strong cancer drugs demand
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo Acquire Licensing Rights Nov 9 (Reuters) - Drugmaker AstraZeneca (AZN.L) raised its annual core profit outlook on Thursday, helped by strong demand for its oncology and rare blood…#astrazeneca #macclesfield (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news
There ’s a Shortage of RSV Treatments. Here’s What Doctors Recommend
A recently approved treatment was supposed to protect babies from RSV, but demand is outpacing the supply of the medication.
The U.S. Food and Drug Administration approved nirsevimab, an antibody that sticks to and prevents Respiratory Syncytial Virus from infecting cells, in July. The Centers for Disease Control and Prevention (CDC) then recommended the medication for all babies either born during the RSV season or those up to eight months old entering their first RSV season, which runs from about November to March. RSV can be a dangerous and potentially deadly disease, especially for infants; about 58,000 to 80,...
Source: TIME: Health - November 2, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
Pfizer Layoffs Confirmed As Vaccine Manufacturer Drives For Cost Savings
Pfizer is laying off an undisclosed amount of employees after confirming it’s shutting down its New Jersey facility • Two other facilities are closing in North Carolina, with other layoffs in Illinois and Colorado • Pfizer’s share price was flat as the company reported a narrower-than-expected…#pfizer #newjersey #northcarolina #illinois #colorado #pfizerspeapack #noncovid #albertboura #q3 #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2023 Category: Consumer Health News Source Type: news
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions
AstraZeneca today announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. (Source: World Pharma News)
Source: World Pharma News - November 1, 2023 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Flu Vaccine That Can Be Used in the Nose at Home, Could Be on Horizon
TUESDAY, Oct. 31, 2023 -- The U.S. Food and Drug Administration is reviewing an application for the at-home use of a nasal spray flu vaccine called FluMist from AstraZeneca. The nasal spray has been on the market since 2003, but AstraZeneca is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2023 Category: Pharmaceuticals Source Type: news
At-Home, Inhaled Flu Vaccine Could Be on Horizon
TUESDAY, Oct. 31, 2023 -- The U.S. Food and Drug Administration is reviewing an application for the at-home use of a nasal spray flu vaccine called FluMist from AstraZeneca. The nasal spray has been on the market since 2003, but AstraZeneca... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2023 Category: Pharmaceuticals Source Type: news
